Kyverna Therapeutics, Inc.
KYTX
$7.66
-$0.19-2.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 140.81% | -341.95% | |||
| Gross Profit | -140.81% | 341.95% | |||
| SG&A Expenses | 21.86% | 12.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.31% | 1.43% | |||
| Operating Income | -5.31% | -1.43% | |||
| Income Before Tax | -5.09% | -2.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.09% | -2.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.09% | -2.76% | |||
| EBIT | -5.31% | -1.43% | |||
| EBITDA | 46.87% | -1.18% | |||
| EPS Basic | 18.00% | 5.38% | |||
| Normalized Basic EPS | 18.00% | 5.38% | |||
| EPS Diluted | 17.67% | 5.38% | |||
| Normalized Diluted EPS | 18.00% | 5.38% | |||
| Average Basic Shares Outstanding | 28.16% | 8.62% | |||
| Average Diluted Shares Outstanding | 28.16% | 8.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||